UCN2 and juvenile dermatomyositis: Given that anti-SRP myositis is usually more resistant to therapy than other forms of adult and juvenile myositis, we suggest that our patient’s results reflect the combination of rituximab together with cyclophosphamide and IVIG rather than from one agent alone.